Genmab Drug Shows Durable Responses in Resistant Ovarian Cancer Trial
Genmab's rinatabart sesutecan demonstrated clinically meaningful responses in a Phase 2 trial for platinum-resistant ovarian cancer patients.
Genmab announced Phase 2 trial results for rinatabart sesutecan, branded as Rina-S, showing durable and clinically meaningful responses in patients with platinum-resistant ovarian cancer, according to data from the RAINFOL-01 study released Wednesday.
Platinum-resistant ovarian cancer represents one of the most difficult-to-treat malignancies in oncology, as patients whose disease progresses during or shortly after platinum-based chemotherapy face severely limited treatment options and poor prognoses. The RAINFOL-01 findings suggest Rina-S may offer a meaningful new avenue for this patient population.
Read more Taysha Gene Therapies Issues Stock Grants to Four New Hires →
The announcement, released through GlobeNewswire, did not include granular efficacy metrics in the available media release text, but Genmab characterized the responses as both durable and clinically significant — language that typically signals sustained tumor reduction over a medically relevant timeframe in oncology trial reporting.
Genmab, a Danish biotechnology company with a focus on antibody-based therapeutics, has positioned rinatabart sesutecan as a key pipeline asset. The drug belongs to the antibody-drug conjugate class, a therapeutic category that has drawn increasing pharmaceutical industry investment for its targeted cancer-cell delivery mechanism.
The Phase 2 data represent an important milestone on the potential regulatory pathway for Rina-S. Positive Phase 2 results in a defined indication like platinum-resistant ovarian cancer can support advancement to confirmatory Phase 3 trials or, in some cases, accelerated approval applications. Continue reading at GlobeNewswire - Industry News on Financial Services.
